What's Your Problem?
Fighting Cancer with CRISPR
May 23, 2024
Rachel Haurwitz, Co-founder and CEO of Caribou Biosciences, discusses using CRISPR to engineer human immune cells to fight cancer. Topics include the journey of CRISPR from breakthrough to FDA approval, enhancing CRISPR's effectiveness, balancing affinity in CRISPR editing, challenges in CAR T-cell therapies for cancer, and reflections on career shifts and gene complexities.
34:41
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Enhancing CRISPR for CAR T-cell therapy development to broaden accessibility and efficiency in cancer treatment.
- Developing CRISPR technologies like Chardonnay to improve editing accuracy and minimize genetic off-target effects.
Deep dives
Overview of CRISPR Technology and Approvals
CRISPR, a revolutionary gene-editing tool, has advanced to the stage of clinical drug approvals, with the first FDA-approved CRISPR-produced therapy for sickle cell and beta thalassemia. Scientists aim to enhance CRISPR for more treatment options. The field has rapidly progressed from foundational research to approved therapies within a remarkably short timeframe.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
